Nymox Corp.

Nymox develops novel therapies for the rapidly aging male population. Its lead drug candidate, Fexapotide for benign prostatic hyperplasia (BHP) has completed phase III trials and the company is in the process of submitting an NDA in Europe and the United States. Fexapotide is also being developed for early-stage prostate cancer. Phase II trials have been completed in the U.S.